1. Academic Validation
  2. Efficient, Selective Removal of Human Pluripotent Stem Cells via Ecto-Alkaline Phosphatase-Mediated Aggregation of Synthetic Peptides

Efficient, Selective Removal of Human Pluripotent Stem Cells via Ecto-Alkaline Phosphatase-Mediated Aggregation of Synthetic Peptides

  • Cell Chem Biol. 2017 Jun 22;24(6):685-694.e4. doi: 10.1016/j.chembiol.2017.04.010.
Yi Kuang 1 Kenji Miki 1 Callum J C Parr 1 Karin Hayashi 1 Ikue Takei 1 Jie Li 2 Mio Iwasaki 1 Masato Nakagawa 1 Yoshinori Yoshida 1 Hirohide Saito 3
Affiliations

Affiliations

  • 1 Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 6068507, Japan.
  • 2 Department of Chemistry, Brandeis University, Waltham, MA 02453, USA.
  • 3 Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 6068507, Japan. Electronic address: [email protected].
Abstract

The incomplete differentiation of human induced pluripotent stem cells (iPSCs) poses a serious safety risk owing to their potential tumorigenicity, hindering their clinical application. Here, we explored the potential of phospho-D-peptides as novel iPSC-eliminating agents. Alkaline phosphatases overexpressed on iPSCs dephosphorylate phospho-D-peptides into hydrophobic Peptides that aggregate and induce cell death. We isolated a peptide candidate, D-3, that selectively and rapidly induced toxicity in iPSCs within 1 hr but had little influence on various non-iPSCs, including primary hepatocytes and iPSC-derived cardiomyocytes. Two hours of D-3 treatment efficiently eliminated iPSCs from both single cultures and co-cultures spiked with increasing ratios of iPSCs. In addition, D-3 prevented residual iPSC-induced teratoma formation in a mouse tumorigenicity assay. These results suggest the enormous potential of D-3 as a low-cost and effective anti-iPSC agent for both laboratory use and for the safe clinical application of iPSC-derived cells in regenerative medicine.

Keywords

anti-iPSC agent; enzymatic induced aggregation; spatial-temporal self-assembly; teratoma prevention.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P2286
    99.49%, IPSC-Eliminating Agent